IDEAS home Printed from https://ideas.repec.org/p/akf/cafewp/36.html
   My bibliography  Save this paper

The role of Health Technology Assessment in reimbursement decisions and pricing of new medicines across diverse healthcare systems

Author

Listed:
  • Perin, Fernanda

Abstract

The rising costs of innovative medicines present a major challenge for public healthcare systems, particularly in countries striving for universal health coverage. Health Technology Assessment (HTA) is critical in guiding reimbursement decisions and negotiating medicine prices, particularly in monopoly markets where pharmaceutical companies hold exclusive rights due to patent protection. This study examines how eight healthcare systems – England, Australia, Canada, Germany, Colombia, Mexico, India, and Brazil – utilise HTA in price negotiations for new medicines. By analysing the integration of HTA into pricing mechanisms, decision-making criteria, and economic evaluation methods, this research highlights significant disparities in terms of socioeconomic context, healthcare system management, and HTA maturity. These insights offer valuable policy recommendations for optimising HTA’s role in controlling medicine prices and ensuring sustainable healthcare financing.

Suggested Citation

  • Perin, Fernanda, 2025. "The role of Health Technology Assessment in reimbursement decisions and pricing of new medicines across diverse healthcare systems," CAFE Working Papers 36, Centre for Accountancy, Finance and Economics (CAFE), Birmingham City Business School, Birmingham City University.
    • Handle: RePEc:akf:cafewp:36
    as

    Download full text from publisher

    File URL: https://www.open-access.bcu.ac.uk/16465/1/Perin%20-%20WP36%20CAFE%20-%20HTA%20medicine%20reimbursement%20and%20pricing.pdf
    Download Restriction: no
    ---><---

    References listed on IDEAS

    as
    1. Mariana Mazzucato & Victor Roy, 2019. "Rethinking value in health innovation: from mystifications towards prescriptions," Journal of Economic Policy Reform, Taylor and Francis Journals, vol. 22(2), pages 101-119, April.
    2. Rosa, Rodriguez-Monguio & Alberto, Infante Campos, 2004. "Universal health care for Colombians 10 years after Law 100: challenges and opportunities," Health Policy, Elsevier, vol. 68(2), pages 129-142, May.
    3. Mariana Mazzucato & Victor Roy, 2019. "Rethinking value in health innovation: from mystifications towards prescriptions," Journal of Economic Policy Reform, Taylor & Francis Journals, vol. 22(2), pages 101-119, April.
    4. CHENG, Nianliang & LI, Hongxia & MENG, Fan & CHAI, Fahe, 2015. "Overview of Urban PM2.5 Numerical Forecast Models in China," Asian Agricultural Research, USA-China Science and Culture Media Corporation, vol. 7(10), pages 1-7, October.
    5. Tubychko K.V. & Zaruba V.Y. & Pignasty O.M. & Khodusov V.D., 2015. "The overview of manufactured systems models," Економічний вісник Донбасу Экономический вестник Донбасса, CyberLeninka;Институт экономики промышленности НАН Украины, issue 4 (42), pages 151-161.
    6. Carlson, Josh J. & Sullivan, Sean D. & Garrison, Louis P. & Neumann, Peter J. & Veenstra, David L., 2010. "Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers," Health Policy, Elsevier, vol. 96(3), pages 179-190, August.
    7. Akudinobi B.E.B. & Egboka B.C.E. & Moore C. & Obiadi I.I., 2015. "Critical Overview of Some Pumping Test Analysis Equations," Scientific Review, Academic Research Publishing Group, vol. 1(7), pages 135-142, 12-2015.
    Full references (including those not matched with items on IDEAS)

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Habib, A. & Ranasinghe, D. & Huang, H.J., 2018. "A literature survey of financial reporting in private firms," Research in Accounting Regulation, Elsevier, vol. 30(1), pages 31-37.
    2. Susan K. Sell, 2020. "What COVID-19 Reveals About Twenty-First Century Capitalism: Adversity and Opportunity," Development, Palgrave Macmillan;Society for International Deveopment, vol. 63(2), pages 150-156, December.
    3. Walsh, P.P. & Murphy, E. & Horan, D., 2020. "The role of science, technology and innovation in the UN 2030 agenda," Technological Forecasting and Social Change, Elsevier, vol. 154(C).
    4. Luca Papi & Riccardo Ievoli & Giorgia Gobbo & Enrico Deidda Gagliardo & Lamberto Manzoli, 2021. "Performance governance per la generazione di Valore Pubblico in sanit?. Evidenze empiriche dalle aziende sanitarie dell?Emilia-Romagna," MECOSAN, FrancoAngeli Editore, vol. 0(117), pages 27-58.
    5. Llewellyn, Sue & Begkos, Christos & Ellwood, Sheila & Mellingwood, Chris, 2022. "Public value and pricing in English hospitals: Value creation or value extraction?," CRITICAL PERSPECTIVES ON ACCOUNTING, Elsevier, vol. 85(C).
    6. Susan K. Sell, 2021. "21st Century Capitalism and Innovation for Health," Global Policy, London School of Economics and Political Science, vol. 12(S6), pages 12-20, July.
    7. Wettstein, Dominik J. & Boes, Stefan, 2022. "How value-based policy interventions influence price negotiations for new medicines: An experimental approach and initial evidence," Health Policy, Elsevier, vol. 126(2), pages 112-121.
    8. Neyt, Mattias & Gerkens, Sophie & San Miguel, Lorena & Vinck, Irm & Thiry, Nancy & Cleemput, Irina, 2020. "An evaluation of managed entry agreements in Belgium: A system with threats and (high) potential if properly applied," Health Policy, Elsevier, vol. 124(9), pages 959-964.
    9. Bognar, Katalin & Romley, John A. & Bae, Jay P. & Murray, James & Chou, Jacquelyn W. & Lakdawalla, Darius N., 2017. "The role of imperfect surrogate endpoint information in drug approval and reimbursement decisions," Journal of Health Economics, Elsevier, vol. 51(C), pages 1-12.
    10. Koster, Hans R.A. & van Ommeren, Jos & Volkhausen, Nicolas, 2021. "Short-term rentals and the housing market: Quasi-experimental evidence from Airbnb in Los Angeles," Journal of Urban Economics, Elsevier, vol. 124(C).
    11. Ferrario, Alessandra & Kanavos, Panos, 2015. "Dealing with uncertainty and high prices of new medicines: A comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden," Social Science & Medicine, Elsevier, vol. 124(C), pages 39-47.
    12. Elodie Adida, 2021. "Outcome-Based Pricing for New Pharmaceuticals via Rebates," Management Science, INFORMS, vol. 67(2), pages 892-913, February.
    13. Bhardwaj, Ramesh, 2015. "Restraining High and Rising Cancer Drug Prices: Need for Accelerating R&D Productivity and Aligning Prices with Value," MPRA Paper 63405, University Library of Munich, Germany.
    14. Bonny Parkinson & Catherine Sermet & Fiona Clement & Steffan Crausaz & Brian Godman & Sarah Garner & Moni Choudhury & Sallie-Anne Pearson & Rosalie Viney & Ruth Lopert & Adam Elshaug, 2015. "Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review," PharmacoEconomics, Springer, vol. 33(9), pages 905-924, September.
    15. Vitry, Agnes & Roughead, Elizabeth, 2014. "Managed entry agreements for pharmaceuticals in Australia," Health Policy, Elsevier, vol. 117(3), pages 345-352.
    16. Goldman Dana P. & Lakdawalla Darius N. & Baumgardner James R. & Linthicum Mark T., 2016. "Are Biopharmaceutical Budget Caps Good Public Policy?," The Economists' Voice, De Gruyter, vol. 13(1), pages 27-42, December.
    17. Simon Walker & Mark Sculpher & Karl Claxton & Steve Palmer, 2012. "Coverage with evidence development, only in research, risk sharing or patient access scheme? A framework for coverage decisions," Working Papers 077cherp, Centre for Health Economics, University of York.
    18. Michael Drummond, 2012. "Economic Evaluation and Decision-makers," Chapters, in: Andrew M. Jones (ed.), The Elgar Companion to Health Economics, Second Edition, chapter 54, Edward Elgar Publishing.
    19. Morgan, Steven G. & Vogler, Sabine & Wagner, Anita K., 2017. "Payers’ experiences with confidential pharmaceutical price discounts: A survey of public and statutory health systems in North America, Europe, and Australasia," Health Policy, Elsevier, vol. 121(4), pages 354-362.
    20. Makady, A. & van Veelen, A. & de Boer, A. & Hillege, H. & Klungel, O.H. & Goettsch, W., 2019. "Implementing managed entry agreements in practice: The Dutch reality check," Health Policy, Elsevier, vol. 123(3), pages 267-274.

    More about this item

    NEP fields

    This paper has been announced in the following NEP Reports:

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:akf:cafewp:36. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Research Publications Librarian (email available below). General contact details of provider: https://edirc.repec.org/data/bsuceuk.html .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.